Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DT45OV
|
|||
| Drug Name |
TAK-831
|
|||
| Synonyms |
Luvadaxistat; 3(2H)-one; UNII-76IC00YRVR; 76IC00YRVR; CHEMBL2338801; 1425511-32-5; 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-; 4-Hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one; 4-Hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)pyridazin-3(2H)-one; Luvadaxistat [USAN]; SCHEMBL14719667; BDBM50431085; WHO 11254; ZINC95592350; 3(2H)-Pyridazinone, 4-hydroxy-6-(2-(4-(trifluoromethyl)phenyl)ethyl)-; 6-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,2-dihydropyridazine-3,4-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Phase 2 | [1] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H11F3N2O2
|
|||
| Canonical SMILES |
C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F
|
|||
| InChI |
1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20)
|
|||
| InChIKey |
QBQMUMMSYHUDFM-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1425511-32-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | D-amino acid oxidase (DAO) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Glycine, serine and threonine metabolism | |||
| Arginine and proline metabolism | ||||
| D-Arginine and D-ornithine metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Peroxisome | ||||
| Pathwhiz Pathway | Arginine and Proline Metabolism | |||
| D-Arginine and D-Ornithine Metabolism | ||||
| WikiPathways | Metabolism of amino acids and derivatives | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03214588) Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia. U.S. National Institutes of Health. | |||
| REF 2 | Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice. Pharm Res. 2020 Aug 5;37(8):164. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.